Home » Topics » Disease categories and therapies » Musculoskeletal

Musculoskeletal
RSS

S-2474: antiarthritic agent with dual NSAID/DMARD profile

Dec. 4, 1997

Amarillo reports positive phase II data in Sjogren's syndrome trial

Dec. 3, 1997

Almirall discloses new COX-2-selective compounds

Dec. 2, 1997

Teva receives FDA approval for generic etodolac

Dec. 1, 1997

JT licenses new oral antiinflammatory agent to R.W. Johnson

Nov. 26, 1997

Anika signs Orthovisc marketing agreement with Zimmer

Nov. 25, 1997

InKine (formerly Panax) completes acquisitions, raises funds for CBP-1011 development

Nov. 21, 1997

Collagenase treatment for Dupuytren's disease enters phase II

Nov. 21, 1997

Phase II results with T-cell receptor peptides in RA promising

Nov. 20, 1997

GL-701 shows significant steroid-sparing effects in women with active SLE

Nov. 20, 1997

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
RX-10616 improves radiotherapy efficacy in HNSCC
BioWorld Science
Head and neck squamous cell carcinoma (HNSCC) accounts for high number of new diagnoses each year. Current management is based on surgery followed by radiotherapy...
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...